Bioelectronics Corp (BIEL)

[srinsocal]

Momentum Building,Major Move Imminent,Good Time for Reflection with 'BIEL's Greatest Hits'

#1) 12/31/2019 - Keith Nalepka, "As 2019 ends, thank you shareholders. 2020 will be BIELs year. Guaranteed. This will be the year we change things, deals done and Actipatch moved forward. Don’t be confused, this is not the same old BIEL. This team is competent, capable and crushing it."
#ihatelosing #teamBIEL

As 2019 ends, thank you shareholders. 2020 will be BIELs year. Guaranteed. This will be the year we change things, deals done and Actipatch moved forward. Don’t be confused, this is not the same old BIEL. This team is competent, capable and crushing it.
#ihatelosing #teamBIEL

— Keith Nalepka (@keith_nalepka) December 31, 2019

<<< a VP and Board of Directors Member does not make this kind of statement unless multiple things are already ‘In The Bag’, KW re-tweeted this post so it also has the CEOs’ blessing>>>

#2) 12/19/2019 - Keith Nalepka, "Today with our Service Disabled Vet partner, Vetguard Supply LLC, we added the McGuire VA as a new account. This is a huge win for us to work through a service disabled vet company to get our product all across the country."

#notdoneyet #12daysofdeals #bielteam #fillingstockings

Today with our Service Disabled Vet partner, Vetguard Supply LLC, we added the McGuire VA as a new account. This is a huge win for us to work through a service disabled vet company to get our product all across the country. #notdoneyet #12daysofdeals #bielteam #fillingstockings

— Keith Nalepka (@keith_nalepka) December 20, 2019

<<< McGuire is an enormous healthcare facility with more than 1 million sq ft of buildings and has 200,000 Veterans in its service area>>>

#3) December 2019 - 29,500 Devices Shipped; Mundipharma Singapore 15,000, Mundipharma Philippines 7,000, Pharmalink UAE 7,500

<<< Depending on the exact Distributor pricing $230k – 330k out the door in one month, the best month for BIEL in several years>>>

#4) 12/10/2019 - "We received the official ISO 13485:2016 certificate from our registrar. This certification is the latest quality management system being utilized in the global medical device industry and will boost the Company’s business credentials. The certificate is valid until December 10, 2022 (3 years) and will be subject to an audit annually.

<<< this is a major regulatory certification used around the world and is the foundation for many government import clearances, completed>>>

#5) 11/15/2019 – BIEL is pleased to announce that after seeking legal counsel a Board of Directors and Company officers have been appointed/re-affirmed.

<<< New Management team at BIEL, New Business plan focusing on OEM Partners, new way of treating Partners, this is BIEL 2.0, ready to close deals and ship product>>>

#6) 11/25/2019 - "Endonovo Therapeutics Inc. filed for Voluntarily Dismissal of its lawsuit against BioElectronics Corp., without prejudice. This move follows Jurisdictional Discovery paperwork filed on November 19, 2019 by the legal counsel representing BioElectronics. BioElectronics is considering its legal options against Endonovo, while prioritizing its resources on closing deals and increasing sales."

<<< this removes a significant burden from BIEL's plate, legal costs should be recoverable from ENDV who also filed 3 other frivolous patent lawsuits against other companies>>>

#7) 10/02/2019 – “Bioelectronics Corp is pleased to announce the publication of a study in the journal Pain Research and Management, titled “A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel OTC Neuromodulation Therapy”. The study demonstrated that users who experience pain relief after using ActiPatch® for 7-days, continued to experience this relief over at least 6-months when ActiPatch® use is continued.”

http://www.bielcorp.com/bioelectronics-announces-publication-of-a-study-of-the-actipatch-medical-device-as-an-effective-long-term-treatment-for-chronic-pain/

<<< some missed the importance of this study, many drug based pain relievers lose some of their effect when used for extended periods, this means upping the dose or changing drugs, ActiPatch does not have this issue>>>

8) 6/28/2019 – RecoveryRx receives FDA 510k Clearance for “Adjunctive treatment of postoperative pain”.

https://www.globenewswire.com/news-release/2019/07/01/1876675/0/en/BioElectronics-Announces-FDA-Market-Clearance-for-Its-Non-Opioid-Postoperative-Pain-Therapy.html

<<< there are 25 million surgeries every year in the US and RecoveryRx can be used on them all, from Head to Toe. With RecoveryRx, exact same device as ActiPatch, Cleared for Full Body how can the FDA deny ActiPatch the same Full Body Clearance?>>>

9) 07/10/2019 – Keith Nalepka is Interviewed on the Stock Day Show.

https://audioboom.com/posts/7311685-the-stock-day-podcast-hosts-bioelectronics-corporation-to-discuss-their-recent-fda-clearance.

<<< a wealth of information in this interview, if you have not listened to it you need to>>>

10) 5/3/2019 - 'I've cured my chronic back pain with £19 patch - but NHS won't prescribe it'

https://www.mirror.co.uk/news/uk-news/ive-cured-chronic-back-pain-14985643

<<< this UK Mirror feature article was free promotion, thousands of dollars worth, for BIEL and places pressure on the NHS to make ActiPatch Available to more patients>>>

11) 03/14/2019 – Mundipharma brings Dr. Sree Koneru to Australia to present Clinical Evidence on the ActiPatch at the Australian Pharmacy Conference.

https://www.mundipharma.com.au/us-expert-presents-evidence-for-actipatch/

<<< further evidence that Mundipharma has gone ‘All In’ with ActiPatch>>>

12) 11/15/2018 - Mundipharma adds 5 countries to its ActiPatch Distributorships, Singapore, Malaysia, Thailand, Indonesia and the Philippines.

<<< Mundipharma adds 5 countries to the initial Australia/New Zealand Distributorship Deal, they obviously like/need ActiPatch, they need to show that they promote pain relievers other than Opioids>>>

13) 11/06/2018 - Pharmacy 4 Less CEO promotes ActiPatch on Australian TV Show.

<<< this is a prime example of what having a Partner with the resources of Mundipharma does for ActiPatch>>>

14) 7/23/2018 - Mundipharma has acquired the exclusive distribution rights for ActiPatch in Australia and New Zealand.

https://www.mundipharma.com.au/mundipharma-broadens-pain-management-portfolio-with-acquisition-of-innovative-physical-therapy-devices/

<<< Mundipharma had to buy out the existing distributor, Evomed, to get the distribution rights to ActiPatch>>>